| Drug Name: | Transforming growth factor beta 1 (TGF beta 1) (CASNA00113) |
|---|---|
| PubChem ID: | |
| SMILES: | |
| InchiKey: | |
| Therapeutic Category: |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cell Death | Glycoprotein hormones (P01215) | TSH and cAMP-dependent DNA synthesis was associated with an inhibition of PCNA (proliferating cell nuclear antigen) synthesis,and led to cell death. [ ADR Type 2 ] | General inhibition by transforming growth factor beta 1 of thyrotropin and cAMP responses in human thyroid cells in primary culture |
| Stimulation Of Dna Synthesis | Epidermal growth factor receptor precursor (P00533) | Inhibition inconstantly the low basal DNA synthesis and strongly the stimulation of DNA synthesis [ ADR Type 2 3 ] | General inhibition by transforming growth factor beta 1 of thyrotropin and cAMP responses in human thyroid cells in primary culture |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|